Close menu

February 24th, 2022 | 13:37 CET

Perimeter, PayPal, Porsche - In the fast lane with high-speed innovations

  • medtech
Photo credits:

Tech values ​​such as PayPal are currently losing a lot of ground. A wonderful exception in these turbulent times are MedTech companies like Perimeter Medical Imaging. The Company has commercialized an imaging technology that confidently assists surgeons in clinical decision-making, further enhancing patient safety in oncology. What is happening at high speed in the healthcare industry outside Germany is impressive. In contrast, Porsche's popular IPO is not quite getting off the ground yet. There are many talks to be held with various board members to bring the brand back to the family.

time to read: 6 minutes | Author: Juliane Zielonka

Table of contents:

    Perimeter - Imaging Technology for cancer surgeons brings safety

    While a major public health insurer in Germany made headlines this week by integrating a fax interface into its digital app, other countries are further ahead in digitization in the healthcare industry.

    Canadian MedTech company Perimeter Medical AI, for example. Their mission: to transform cancer surgery with ultra-high resolution, advanced imaging tools in real-time. So far, here is how it works in oncology: a surgeon operating on a cancerous tumor from a patient sends a sample of the tumor to a lab for further analysis. The lab is located outside the hospital, and therefore it takes between two and seven days to determine the type of cancer accurately. This situation is unpleasant for both the patient and the doctor - up to seven days of worry and uncertainty as to whether cancer may have spread further in the body. In the laboratory, the pathologist looks for cancer cells at the edge of the tissue. If he finds cancer at the edge of the sample, the likelihood of cancer recurrence in that patient dramatically increases.

    Breast cancer surgery in which the breast is to be preserved doubles the risk for patients that cancer will recur. Previously, the doctor would then operate again a little later. Perimeter technology allows surgeons to see the edge of the tumor in real-time in the operating room to remove additional tissue immediately if they wish - greater safety for the patient, the physician, and right on site.

    With Perimeter Medical Imaging, the physician always has the power of interpretation. Positioning is thus clearly a clinical decision support tool. CEO Jeremy Sobotta comments, "having this information in the operating room allows us to avoid the need for a second surgery. That is what the real value is. It is the time in which we have that information." Technology, he said, empowers physicians to provide the best possible care to patients and gives them the ability to make decisions right on the spot using valid data.

    Does that even compute in a world of government payment, diagnosis-related groups and per-surgery reimbursements? Sobotta has an answer for that, too: "You effectively have a CAD 4,000 cost per patient and potentially avoidable reoperation costs. Almost certainly, physicians using this technology can expect a reduction in reoperation rates of at least 50%. So we have cut the cost in half from CAD 4,000 to CAD 2,000, creating a value of CAD 2,000. For payers, it is an elegant 50/50 split. They pay Perimeter CAD 1,000 per procedure. So CAD 1,000 to Perimeter and CAD 1,000 to payers is a pretty elegant kind of 50/50 split from a value-added perspective."

    What is interesting about Perimeter is the Company is just beginning to commercialize its artificial intelligence-enabled product. This is an opportunity for investors to support a company's growth from the start and benefit from this groundbreaking technology.

    PayPal - Lots of cash makes the Company attractive

    Artificial Intelligence has found its way into the financial sector. We all know the situation: someone orders a money tree table lamp fresh from Wuhan in a dropshipping store, pays with PayPal and what happens? The deal falls through because the buyer's account is not funded. Annoying. False credit and debit card rejections cost real money. A 2020 study found that merchants in Germany, France, the UK and the US lost about USD 20.3 billion in 2019 due to incorrect card rejections. More than 60% of that amount - USD 12.7 billion - went to competing websites. The rest, USD 7.6 billion, was simply lost.

    To combat payment fraud, PayPal has developed Fraud Protection. An "adaptive machine learning solution that helps merchants protect themselves from fraud." PayPal affirms that the solution's strength in detecting fraud comes from the Company's vast data assets.

    Unfortunately, despite the innovations coming out of Silicon Valley, PayPal's stock price has nearly halved. In 2022 alone, the payment service provider's stock has fallen more than 44% due to disappointing forecasts. Inflation and the looming rise in interest rates drove investors to value stocks in recent weeks.

    But a look at PayPal's balance sheet offers hope. The Company had debt of about USD 9 billion, but also cash, cash equivalents and investments of USD 16.3 billion. So the Company has plenty of cash. In addition, PayPal ended last year on a positive note, as it generated USD 1.8 billion in operating cash flow in the fourth quarter of 2021. This figure represents a 31% YOY increase.

    Also, in Q4 2021, PayPal reported a free cash flow of USD 1.6 billion, a 38% YOY increase. As a payment option for small and large merchants worldwide, PayPal is here to stay. Now let's hope that the platform giant has consolidated in terms of its share price.

    Porsche - Back to the family

    There is no talk of high-speed speed in the planned Porsche IPO. On Tuesday of this week, Volkswagen confirmed long-circulated talks with its majority shareholder Porsche SE about an IPO of its sports car brand, Porsche AG. Porsche SE is a listed holding company and used to own the manufacturer of the same name. But it lost direct control in the 2008 short squeeze.

    Porsche SE has made it clear that it wants the brand back. Back to the family, in other words. Because in the SE, the Porsche-Piëch family holds the absolute majority of the votes (53.3%). An undertaking that depends on the approval of the members of the various supervisory boards of the different entities. According to analysts, the Stuttgart-based sports car manufacturer could be worth EUR 85 billion, which would make it one of the largest IPOs in Frankfurt in years. The IPO is shaping into a complex undertaking, as Porsche SE controls the Volkswagen Group itself.

    According to information from Handelsblatt, Volkswagen is in advanced talks with its main shareholder to reach an agreement that would lay the groundwork for an IPO of Porsche with up to 49% of the total capital.

    Porsche CEO Oliver Blume is optimistic despite the semiconductor crisis and the Corona pandemic: "We have become even more focused. For example, we paid close attention to our fixed costs from the beginning of the pandemic. That has allowed us to lower the break-even point further and put us in an even stronger financial position, with the clear goal of maintaining our ambitious 15% margin target for 2022."

    Porsche's self-confidence is also growing with its success. Says Blume: "For me, it is less about self-confidence and more about entrepreneurship. We have been successful with this for years. We use components from the Volkswagen Group and vice versa. The important thing is that Porsche's success also benefits the Group as a whole."

    Porsche enthusiasts are generally academics with a household income of around EUR 90,000, 85% men and 15% women. The typical Porsche owner is 40 years old and older. A brand-new Porsche 911 can be bought for a slim EUR 111,231.

    If you want to invest in a beneficial product with an expandable future, you are in a good position with Perimeter Medical Imaging. Innovations in medicine always require scientific research to find their way into everyday clinical practice. Therefore, twice as safe. Platform giant PayPal seems to consolidate and offers the opportunity to buy up. Porsche steps on the gas and wants to go back to the family. The IPO seems to be less in the interest of the shareholders than in the self-interest of the majority shares to the brand.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by Juliane Zielonka on April 21st, 2022 | 13:58 CEST

    Bayer AG, Perimeter Medical, Twitter - Shareholder interests drive share price performance

    • medtech
    • Technology

    The life science and medical technology sectors offer investment opportunities. Whether with old hands like Bayer AG or up-and-coming innovative startups like Perimeter Medical, each company has its own fascination. Strong corporate management that acts in the interests of shareholders provides additional confidence. The latter, in particular, is currently being put to the test at the short messaging service Twitter. Elon Musk's takeover bid threatens to dilute existing investors' shares with a poison pill.


    Commented by André Will-Laudien on April 6th, 2022 | 10:46 CEST

    Siemens Healthineers, Perimeter Medical, Siemens, SAP - After BioNTech, now the push for MedTech shares!

    • medtech
    • Biotechnology
    • Software

    The most significant positive share price developments in the last 12 months occurred in the biotech sector, especially among vaccine manufacturers such as BioNTech and Moderna. The stock market overlooked that pandemics, and the fight against them, offer short-term profit opportunities. The great battle against widespread diseases such as cardiovascular disease, cancer or other previously incurable indications progresses steadily. Their diagnosis and treatment require many types of technology, devices, processes, analysis tools, and intelligent software. Some methods certainly deserve the attribute "disruptive technology". We take a look at some blockbusters in the MedTech segment.


    Commented by Armin Schulz on April 1st, 2022 | 12:54 CEST

    Plug Power, Perimeter Medical Imaging AI, JinkoSolar - Shares for the future

    • medtech
    • GreenTech
    • Hydrogen

    Since the Ukraine crisis at the latest, it has been clear that the energy policy will have to look different in the future. While the end of fossil fuels has been heralded before, the transition must now happen faster than initially planned. Hydrogen could play a major role in heavy-duty transportation and energy-intensive industries. In electricity, renewables such as wind and solar power are expected to play a key role. But there are promising developments not only in the energy sector but also in medical technology. Cancer is on the rise worldwide, and any development that helps fight it is welcome. Today we look at stocks from the hydrogen, medical technology and solar power sectors.